PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

The judge's ruling adds to a growing number of legal decisions halting or scaling back the administration’s actions.

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

Medical school attrition rates are higher among lesbian, gay, and bisexual (LGB) medical students than among their non-LGB peers.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

A new SARS-CoV-2 variant, NB.1.8.1, may now account for more than one-third of all COVID-19 cases in the US, health officials say.